13 results on '"Zuckerman, Hannah"'
Search Results
2. Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder
- Author
-
Park, Caroline, Zuckerman, Hannah, Subramaniapillai, Mehala, Mansur, Rodrigo B., Rosenblat, Joshua D., Cao, Bing, Iacobucci, Michelle, Lee, Yena, Levitan, Robert, Blumberger, Daniel M., and McIntyre, Roger S.
- Published
- 2020
- Full Text
- View/download PDF
3. Effort-based decision-making is affected by overweight/obesity in major depressive disorder
- Author
-
Mansur, Rodrigo B., Subramaniapillai, Mehala, Zuckerman, Hannah, Park, Caroline, Iacobucci, Michelle, Lee, Yena, Tuineag, Maria, Hawco, Colin, Frey, Benicio N., Rasgon, Natalie, Brietzke, Elisa, and McIntyre, Roger S.
- Published
- 2019
- Full Text
- View/download PDF
4. Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review
- Author
-
Lee, Yena, Ragguett, Renee-Marie, Mansur, Rodrigo B., Boutilier, Justin J., Rosenblat, Joshua D., Trevizol, Alisson, Brietzke, Elisa, Lin, Kangguang, Pan, Zihang, Subramaniapillai, Mehala, Chan, Timothy C.Y., Fus, Dominika, Park, Caroline, Musial, Natalie, Zuckerman, Hannah, Chen, Vincent Chin-Hung, Ho, Roger, Rong, Carola, and McIntyre, Roger S.
- Published
- 2018
- Full Text
- View/download PDF
5. Leptin and adiponectin levels in major depressive disorder: A systematic review and meta-analysis
- Author
-
Cao, Bing, Chen, Yan, Brietzke, Elisa, Cha, Danielle, Shaukat, Aisha, Pan, Zihang, Park, Caroline, Subramaniapillai, Mehala, Zuckerman, Hannah, Grant, Kiran, Mansur, Rodrigo B., and McIntyre, Roger S.
- Published
- 2018
- Full Text
- View/download PDF
6. Corrigendum to “Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review.” J Affect Disord. 241 (2018) 519-532
- Author
-
Lee, Yena, Ragguett, Renee-Marie, Mansur, Rodrigo B., Boutilier, Justin J., Rosenblat, Joshua D., Trevizol, Alisson, Brietzke, Elisa, Lin, Kangguang, Pan, Zihang, Subramaniapillai, Mehala, Chan, Timothy C.Y., Fus, Dominika, Park, Caroline, Musial, Natalie, Zuckerman, Hannah, Chen, Vincent Chin-Hung, Ho, Roger, Rong, Carola, and McIntyre, Roger S.
- Published
- 2020
- Full Text
- View/download PDF
7. Comparison of serum essential trace metals between patients with schizophrenia and healthy controls.
- Author
-
Cao, Bing, Yan, Lailai, Ma, Jiahui, Jin, Min, Park, Caroline, Nozari, Yasaman, Kazmierczak, Olivia P., Zuckerman, Hannah, Lee, Yena, Pan, Zihang, Brietzke, Elisa, McIntyre, Roger S., Lui, Leanna M.W., Li, Nan, and Wang, Jingyu
- Subjects
TRACE metals ,DIAGNOSIS of schizophrenia ,BLOOD serum analysis ,PUBLIC health ,PATHOLOGICAL physiology - Abstract
Highlights • Fe, Zn, Cu, Co, Mn, Ni and Mo are seven typical essential trace metals related to human health. • This case-control study aimed to evaluate the association between ETMs and schizophrenia. • Lower serum concentrations of Mn and Mo were found in patients with schizophrenia. • Serum concentrations of Fe and Ni were significantly higher in patients with schizophrenia than HCs. • Correlations between specific ETMs and liver and renal function were found in patients with schizophrenia Abstract Preclinical and clinical studies have suggested that essential trace metals (ETMs) play an important role in the pathophysiology of brain-based disorders, including schizophrenia. This case-control study aimed to evaluate the association between ETMs and schizophrenia, and to further examine the association between ETMs and clinical characteristics in schizophrenia. One-hundred and five (n = 105) subjects who meet DSM-IV criteria for schizophrenia between the ages of 18 and 40 were recruited for the study. One hundred and six (n = 106) age- and sex-matched healthy controls (HCs) were recruited for comparison. Serum concentrations of seven ETMs [i.e. iron (Fe), zinc (Zn), copper (Cu), cobalt (Co), manganese (Mn), nickel (Ni) and molybdenum (Mo)] were evaluated using inductively coupled plasma mass spectrometry, which allows for the quantitative analysis of multiple ETMs at a single time point. Compared to HCs, serum concentrations of Mn and Mo were significantly lower in patients with schizophrenia. In contrast, serum concentrations of Fe and Ni were significantly higher in patients with schizophrenia. Additionally, correlations between specific ETMs and metabolic parameters (particularly those related to liver and renal function) were found in patients with schizophrenia, and the correlations between every two ETMs in HCs were widely interrupted. Differential levels of selected ETMs (i.e., Mn, Mo, and Ni) were identified between patients with schizophrenia and HCs following adjustment for potential confounders. The findings here should therefore be evaluated in future studies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine.
- Author
-
Subramaniapillai, Mehala, Mansur, Rodrigo B., Zuckerman, Hannah, Park, Caroline, Lee, Yena, Iacobucci, Michelle, Cao, Bing, Ho, Roger, Lin, Kangguang, Phan, Lee, and McIntyre, Roger S.
- Abstract
It is well established that deficits in motivation, reward, and cognition are common during and in between syndromal episodes of depression as part of Major Depressive Disorder (MDD). Informed by evidence indicating functional and structural interconnectivity between cognitive and reward brain circuits, we preliminarily evaluate the association between measures of cognitive performance and reward/motivation. This is a post-hoc analysis of a primary study (i.e. the THINC-it sensitivity to change study). Adults (18–65 years of age) meeting DSM-5 criteria for MDD, single-episode or recurrent confirmed by M.I.N.I. with moderate severity or greater (i.e. Montgomery Asberg Depression Rating Scale ≥20). All eligible subjects received vortioxetine 10–20 mg open-label for 8 weeks. The Effort Expenditure Reward Task (EEfRT) was the principal measure of motivation and reward. We directly compare the effects of cognitive measures and depressive symptoms on effort-based decision-making using the THINC-it composite score and MADRS total score. Twenty-one participants with MDD (Mean age = 38.47, SD = 12.85) and 20 healthy volunteers (Mean age = 41.50, SD = 14.21) completed the optional EEfRT task. Amongst individuals with MDD, performance in processing speed, executive function (i.e. Trails B) and overall composite cognitive score was positively associated with the proportion of hard-task choices in the high reward condition (i.e. greater reward valuation). Across both groups, a greater probability (χ
2 = 1.137) and magnitude of reward (χ2 = 0.045) was associated with increased effort (i.e. choosing the hard task more frequently). Using fully factored GEE models, we observed a positive association between performance on the Trails test (β = 2.223, SE = 0.928, p = 0.017) as well as the composite score (β = 0.978, SE = 0.0.459, p = 0.033), and greater effort for high rewards. In addition, it was observed that a positive association (i.e. greater effort for reward in higher probability) was observed with depressive symptoms and overall cognitive measures. Herein, we observed that an association exists between overall cognitive function, notably processing speed and executive function and reward function. Specifically, a greater effort for hard task rewards (using the EEfRT task) was manifested in individuals exhibiting higher levels of cognitive performance in a well-characterized sample of MDD treated with Vortioxetine. • Cognitive function highly correlates with measures of reward and motivation in adults with major depressive disorder (MDD) • Processing speed, executive function and overall cognition was positively associated with greater reward valuation • Overall cognition positively correlated (i.e. greater effort for reward in higher probability) with depressive symptoms • Self-reported measures of anhedonia and reward valuation are distinct domains of psychopathology in those with MDD [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
9. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review.
- Author
-
Cao, Bing, Zhu, Judy, Zuckerman, Hannah, Rosenblat, Joshua D., Brietzke, Elisa, Pan, Zihang, Subramanieapillai, Mehala, Park, Caroline, Lee, Yena, and McIntyre, Roger S.
- Subjects
- *
MENTAL depression , *DULOXETINE , *RILUZOLE , *META-analysis , *ANHEDONIA , *EXCITATORY amino acid agents , *THERAPEUTICS - Abstract
Anhedonia is defined as a diminished ability to experience interest or pleasure, and is a critical psychopathological dimension of major depressive disorder (MDD). The purpose of the current systematic review is to evaluate the therapeutic efficacy of pharmacological treatments on measures of anhedonia in adults with MDD. Electronic databases Cochrane Library (CENTRAL), Ovid MEDLINE, PubMed, PsycINFO, and Google Scholar were searched from inception to June 1, 2018 for longitudinal studies utilizing pharmacotherapy for the treatment of anhedonia in patients with MDD. A total of 17 eligible studies were identified (i.e., evaluated the effects of pharmacotherapy on a measure of anhedonia). Among the identified studies, the efficacy of 14 different pharmacotherapies on measures of anhedonia were evaluated, including melatonergic agents (i.e. agomelatine), monoaminergic agents (i.e. moclobemide, clomipramine, bupropion, venlafaxine, fluoxetine, amitifadine and levomilnacipran, escitalopram, and sertraline), glutamatergic agents (i.e., ketamine and riluzole), stimulants (i.e., methylphenidate), and psychedelics (i.e., psilocybin). Based on the available evidence, most antidepressants demonstrated beneficial effects on measures of anhedonia as well as the other depressive symptoms. Only escitalopram/riluzole combination treatment was ineffective in treating symptoms of anhedonia in MDD. Continued research is warranted to further support the efficacy of mechanistically-distinct antidepressants in treating symptoms of anhedonia in MDD. Future research should also aim to parse out the heterogeneous effects of different pharmacotherapies on anhedonic symptoms. • Majority of antidepressants do not show pronounced collinear improvements in anhedonia and other depressive symptoms. • Therapies targeting melatonergic receptors and circadian rhythm imbalances are more direct targets for treating anhedonia. • Ketamine may be faster acting of anti-anhedonia due to direct effect on mitochondrial energy metabolism. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Stress, epigenetics and depression: A systematic review.
- Author
-
Park, Caroline, Rosenblat, Joshua D., Brietzke, Elisa, Pan, Zihang, Lee, Yena, Cao, Bing, Zuckerman, Hannah, Kalantarova, Anastasia, and McIntyre, Roger S.
- Subjects
- *
META-analysis , *DNA structure , *GENE expression , *DNA methylation - Abstract
• Childhood maltreatment is an important stressor associated with stress & depression. • Stress- and depression-associated changes were mostly found in NRC31 and SLCA4. • Epigenetic changes occurring at different loci may have variable downstream effects. • Most studies measured epigenetic changes using peripheral tissue samples. • Future studies should evaluate epigenetic effects of psychotropic medication use. Environmental stressors, such as childhood maltreatment, have been recognized to contribute to the development of depression. Growing evidence suggests that epigenetic changes are a key mechanism by which stressors interact with the genome leading to stable changes in DNA structure, gene expression, and behaviour. The current review aimed to evaluate the relationship between stress-associated epigenetic changes and depression. Human studies were identified via systematic searching of PubMed/Medline from inception to February 2018. Seventeen articles were identified. Stress-associated epigenetic changes in the following genes were correlated with depression: NRC31, SLCA4, BDNF, FKBP5, SKA2, OXTR , LINGO3, POU3F1 and ITGB1. Epigenetic changes in glucocorticoid signaling (e.g., NR3C1, FKBP5), serotonergic signaling (e.g. SLC6A4), and neurotrophin (e.g., BDNF) genes appear to be the most promising therapeutic targets for future research. However, continued research is warranted due to inconsistent findings regarding the directionality of epigenetic modification. Future studies should also aim to control for the use of psychotropic agents due to their widespread use in depressed populations and established effects on DNA methylation. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. The long-term effect of bariatric surgery on depression and anxiety.
- Author
-
Gill, Hartej, Kang, Simratdeep, Lee, Yena, Rosenblat, Joshua D., Brietzke, Elisa, Zuckerman, Hannah, and McIntyre, Roger S.
- Subjects
- *
BARIATRIC surgery , *OBESITY , *ANXIETY , *AFFECTIVE disorders , *MENTAL depression , *PSYCHOLOGY information storage & retrieval systems , *MEDLINE , *ONLINE information services , *SYSTEMATIC reviews , *MORBID obesity - Abstract
Background: No previous review has comprehensively assessed long-term changes in anxiety and depressive symptoms in bariatric surgery patients. This systematic review assessed the effects of bariatric surgery on long-term reductions (≥ 24 months) in anxiety and depressive symptom severity in morbidly obese (≥ 35 BMI kg/m2) participants. Short term effects (< 24 months) are briefly reviewed for context.Methods: PsychINFO, Google Scholar and PubMed databases were systematically searched for prospective cohort studies published from inception to 14 June 2018 that evaluated long-term (≥ 24 months) changes in anxiety and depressive symptom severity in bariatric surgery patients with a BMI ≥ 35 kg/m2 using a combination of the following search terms: bariatric surgery (and surgical approaches included under this term), obesity, depression, depressive disorder, anxiety, anxious, psychiatric disorders, mood disorders.Results: We reviewed 2058 articles for eligibility; 14 prospective studies were included in the systematic review. 13 studies (93%) reported significant reductions in depressive symptom severity 2-3 years after bariatric surgery. However, all studies recorded statistically significant reductions in depressive symptoms at the conclusion of the study. Similarly, there were reductions in overall anxiety symptom severity at ≥ 24 months follow-up (k = 8 studies, n = 1590 pooled). Pre-operative anxiety or depression scores did not predict outcomes of post-operative BMI. Similarly, post-surgery weight loss did not predict changes in anxiety symptoms.Limitations: Very few studies assessed anxiety or depression as a primary outcome. Therefore, we cannot suggest bariatric surgery as a stand-alone therapeutic tool for anxiety and depression based on our findings.Conclusion: Currently available evidence suggests that bariatric surgery is associated with long-term reductions in anxiety and depressive symptoms. This supports existing literature showing that metabolic treatments may be a viable therapeutic intervention for mood disorders. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
12. Predicting antidepressant response using early changes in cognition: A systematic review.
- Author
-
Park, Caroline, Pan, Zihang, Brietzke, Elisa, Subramaniapillai, Mehala, Rosenblat, Joshua D., Zuckerman, Hannah, Lee, Yena, Fus, Dominika, and McIntyre, Roger S.
- Subjects
- *
ANTIDEPRESSANTS , *PSYCHIATRIC drugs , *NEURAL circuitry , *NEURAL transmission , *DRUG therapy - Abstract
Background Despite the widespread use of antidepressants in clinical practice, the current trial-and-error approach to medication selection contributes to treatment failure and underscores the need to identify reliable predictors of antidepressant response. Since changes in measures of cognition have been reported to occur early in treatment and prior to improvements in overall mood symptoms, the present review aims to determine whether early changes in measures of cognition can predict response in individuals with MDD. Methods A systematic review of studies evaluating early cognitive change as a predictor of later treatment response in MDD was conducted using PubMed/Medline, Embase and PsychINFO. Results A total of seven articles were identified. The available evidence suggests the early changes in cognition may predict treatment response in individuals with MDD. This was shown across antidepressant classes (i.e., SSRIs, SNRIs, NRIs, melatonergic antidepressants) and forms of therapy (i.e., pharmacotherapy, rTMS). The results depict an emerging trend towards early changes in facial emotion recognition (i.e., a hot cognitive process) as a predictor of treatment outcome. Limitations Our qualitative analysis reflects a very limited number of studies. Moreover, there was significant heterogeneity in the evaluation of cognition across studies. Future research should aim to parse out this heterogeneity by evaluating the relative predictive value of different measures of cognition. Conclusion The identification of reliable early treatment predictors of antidepressant response would be clinically significant, enabling clinicians to more accurately evaluate the efficacy of selected treatment avenues. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. Evidence supporting a mechanistic role of sirtuins in mood and metabolic disorders.
- Author
-
Alageel, Asem, Tomasi, Julia, Tersigni, Claudia, Brietzke, Elisa, Zuckerman, Hannah, Subramaniapillai, Mehala, Lee, Yena, Iacobucci, Michelle, Rosenblat, Joshua D., Mansur, Rodrigo B., and McIntyre, Roger S.
- Subjects
- *
SIRTUINS , *AFFECTIVE disorders , *METABOLIC disorders , *HISTONE deacetylase , *INFLAMMATION - Abstract
Sirtuins are NAD + -dependent histone deacetylases that play essential roles in cell survival, energy metabolism, inflammation, and aging; therefore, sirtuins are potential therapeutic targets in the treatment of type 2 diabetes, cancer, inflammatory and metabolic disorders, and neurodegenerative diseases. Available evidence provides the basis for hypothesizing that sirtuins 1, 2, and 3 (SIRT1, SIRT2, and SIRT3) may have a mechanistic role subserving mood disorders (i.e. downregulation) and associated co-morbidity (e.g. metabolic disorders). Specifically, the domains of general cognitive processes, as well as cognitive emotional processing may be particularly relevant to sirtuin physiology. Given the role of sirtuins in the perpetuation of circadian rhythmicity, and evidence of dysfunctional circadian cycling in mood disorders, sirtuins may be an underlying etiological factor that links circadian rhythm functionality with mood disorders. Caloric restriction, and caloric restriction mimetics (e.g. resveratrol) are all capable of upregulating sirtuin isoforms implicated in stress response syndromes. Repurposing existing treatments and/or discovery of novel agents capable of modulating sirtuin physiology may represent genuinely novel approaches for trans-diagnostic domains affected in mood disorders and other brain-based illnesses. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.